Inhibition of murine corneal allograft rejection by treatment with antibodies to CD80 and CD86

The purpose of this study was to investigate the role of CD80 and CD86 costimulatory molecules in corneal allograft rejection. Anti-CD80 and anti-CD86 monoclonal antibodies (mAbs) were administered after orthotopic corneal allograft transplantation. Graft rejection was observed by biomicroscopy. Population and localization of CD80(+) and CD86(+) cells in the cornea, cervical lymph nodes, and spleen were examined by flow cytometry and immunohistochemistry, The combined use of anti-CD80 and anti-CD86 mAbs was effective in prolonging corneal allograft survival. In the untreated mice bearing rejected graft, many CD86(+) and CD80(+) cells were found around the host-graft junctional area in the cornea. and CD86 high cells were found in the cervical lymph node and spleen. In contrast, few CD86(+) or CD80(+) cells were observed in the cornea, cervical lymph node, and spleen from the mice treated with antiCD80/CD86 mAbs. These results demonstrated a significant role of CD80 and CD86 costimulatory molecules in corneal allograft rejection. (C) 2002 Elsevier Science Ltd.